Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 4, 2020

UK researchers launch trial of blood plasma therapy for Covid-19

Researchers at Guy's and St Thomas' NHS Foundation Trust in the UK have launched a clinical trial to assess blood plasma therapy for Covid-19 treatment.

Researchers at Guy’s and St Thomas’ NHS Foundation Trust in the UK have launched a clinical trial to assess blood plasma therapy for Covid-19 treatment.

Guy’s and St Thomas’ is one of the first sites participating in the REMAP-CAP trial, which is assessing various therapies for severely ill patients.

The plasma therapy, called convalescent plasma treatment, requires blood plasma donations from people who have recovered from Covid-19.

This plasma is administered to Covid-19 patients who could not generate sufficient antibodies against the virus.

Guy’s and St Thomas’ clinician scientist Dr Manu Shankar-Hari said: “At the moment, there is no proven treatment for Covid-19.

“Convalescent plasma is a promising treatment that could help patients whose bodies aren’t producing enough antibodies to curb the disease. This trial will help us understand whether the treatment should be used more widely to treat Covid-19.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

With support from UK National Institute for Health Research (NIHR), the trial is co-led by Dr Shankar-Hari with NHS Blood and Transplant and University of Cambridge experts.

Last month, the UK Government approved a national clinical trial to assess plasma therapy for the treatment of Covid-19 patients.

The trial will assess the effectiveness of convalescent plasma, which is obtained from recovered patients, in severely ill Covid-19 patients.

A scaled-up national programme, if effective, will supply up to 10,000 units of convalescent plasma each week to the NHS, enabling the treatment of 5,000 patients per week.

Researchers will use plasma from patients who have recovered for at least 28 days to ensure increased antibody levels.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy